The secret of a successful academia-industry partnership
This year’s recipient of the TAT Honorary Award Prof. Ruth Plummer, retraces the most significant milestones of her career in early phase studies
Past editions
Cancer screening programmes, a long road back to normal
"Oncologists have learnt many lessons from the COVID-19 pandemic"
Dr Stefan Zimmermann, ESMO Perspectives Editor-in-Chief, explains the key aspects of a new scenario in oncology emerging from the COVID-19 pandemic.
Is COVID-19 turning back the clock for patient empowerment?
Increased bureaucracy downgrades efficiency in cancer research
Does academic research really need so much administrative work?
It is time to extend the continuity of cancer care beyond hospital walls
“What would have been unthinkable before became feasible in the interest of patient safety”
Young oncologists in the coronavirus crisis: a learning opportunity
Despite some share the concern of having their career plans delayed or disrupted by the pandemic, the new challenges emerged in these unprecedented times represent a unique opportunity to grow-up as oncology professionals and get ready to a new scenario where team working, humanisation of care and virtual education will be more crucial than ever.
Telemedicine: the good and bad of living a hype
Patients with cancer and research: will COVID-19 further damage opportunities to join experimental trials?
How to make the right therapeutic choice for cancer patients at a time of crisis
“I have learnt how to be a global oncologist”
2019 marks the 30th Anniversary of the ESMO Fellowship Programme, a programme that has helped young oncologists to enhance their careers like Giannis Mountzios, Henry Dunant Hospital Center, Athens, Greece, who had the opportunity to broaden his experience internationally.
“Choose the right projects and you will always love your work”
Françoise Mornex, Université Claude Bernard, Lyon, France, made history this year when she became the first woman to receive the Heine H. Hansen Award, in recognition of her contribution to the field of lung cancer. She talks about her passion for her work and teaching and keeping the flame of interest alight.
The time to act is now
Shortages of inexpensive essential cancer medicines is a growing emergency in Europe, although the size of the problem is still uncertain as data are lacking. ESMO is at the forefront in order to drive concerted and collaborative action. A call to action was launched last April as the issue cannot be tackled by countries individually and establishing a strong European leadership is crucial.
Nurture young oncologists in Asia
LGP in Asia
The first ESMO Leaders Generation Programme (LGP) Asia will be a four-day course held in Singapore from 18 to 21 November 2019. The course will provide participants with an overview of how ESMO works, offering workshops, discussions and hands-on media and leadership skills training. The programme is aimed at qualified medical or clinical oncologists, working in the Asia-Pacific region and who are ESMO members aged between 31 and 45.
Beyond blood with liquid biopsies
Pioneering work by Joan Seoane and colleagues from Vall d’Hebron Institute of Oncology in Barcelona makes use of cerebrospinal fluid (CSF) to detect circulating tumour DNA (ctDNA) in patients with brain tumours. Where blood and plasma analysis have failed, a new era for liquid biopsies based on different physiological fluids for different tumour types is on the horizon.
Why we need to investigate sex differences in cancer research
An innovative approach
Sex- and gender-sensitive medicine postulates that differences in biological sex, gender identity, role and relations all impact health and disease, and may have implications for prevention, screening, diagnosis and treatment. Its goal is to learn from these differences to improve care and treatment for men and women.
Integrating the patient’s voice into clinical settings
While patient-reported outcomes (PROs) are now an integral part of many phase III trials, their incorporation into routine clinical practice is hampered by economic and time pressures among healthcare professionals. However, with the advent of electronic-based questionnaires, current boundaries are likely to be stretched.
What should oncologists know about e-cigarettes?
Electronic nicotine delivery systems (ENDS) are battery-powered products that create an aerosol by heating a liquid consisting of propylene glycol and vegetable glycerin and flavouring agents. The liquid may or may not (but usually does) contain nicotine, at variable doses. Differently from conventional cigarettes, there is no combustion of tobacco in ENDS, thus making people think they cause less harm. However, the varying voltage that is applied to the liquid creates a mixture of potentially toxic substances in the aerosols that are then inhaled by users.
Translating commitments into action
The World Health Organization (WHO) defines a National Cancer Control Plan as ‘a public health programme designed to reduce cancer incidence and mortality and improve quality of life of cancer patients, through the systematic and equitable implementation of evidence-based strategies for prevention, early detection, diagnosis, treatment, and palliation, making the best use of available resources’.
Boundaries
Read all articles from Edition 8 of the ESMO Perspectives.
Challenges
Read all articles from Edition 7 of the ESMO Perspectives.
Collaboration
Read all articles from Edition 6 of the ESMO Perspectives.
The Future
Read all articles from Edition 1 of the ESMO Perspectives.